PD16-07 NEUTROPHIL-TO-LYMPHOCYTE RATIO IN UNCLASSIFIED RENAL CELL CARCINOMA IS ASSOCIATED WITH OUTCOME AND DIFFERS BETWEEN MOLECULAR SUBGROUPS

Abstract

Listen

Translate article

You have accessJournal of UrologyKidney Cancer: Localized: Surgical Therapy II (PD16)1 Sep 2021PD16-07 NEUTROPHIL-TO-LYMPHOCYTE RATIO IN UNCLASSIFIED RENAL CELL CARCINOMA IS ASSOCIATED WITH OUTCOME AND DIFFERS BETWEEN MOLECULAR SUBGROUPS Julian Marcon, Renzo G. DiNatale, Stanley Weng, Mazyar Ghanaat, Andrew W. Silagy, Roy Mano, Kyle A. Blum, Kyrollis Attalla, Ed Reznik, Maria I. Carlo, Robert J. Motzer, Jonathan A. Coleman, Paul Russo, A. Ari Hakimi, and Ying-Bei Chen Julian MarconJulian Marcon More articles by this author , Renzo G. DiNataleRenzo G. DiNatale More articles by this author , Stanley WengStanley Weng More articles by this author , Mazyar GhanaatMazyar Ghanaat More articles by this author , Andrew W. SilagyAndrew W. Silagy More articles by this author , Roy ManoRoy Mano More articles by this author , Kyle A. BlumKyle A. Blum More articles by this author , Kyrollis AttallaKyrollis Attalla More articles by this author , Ed ReznikEd Reznik More articles by this author , Maria I. CarloMaria I. Carlo More articles by this author , Robert J. MotzerRobert J. Motzer More articles by this author , Jonathan A. ColemanJonathan A. Coleman More articles by this author , Paul RussoPaul Russo More articles by this author , A. Ari HakimiA. Ari Hakimi More articles by this author , and Ying-Bei ChenYing-Bei Chen More articles by this author View All Author Informationhttps://doi.org/10.1097/JU.0000000000001998.07AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract INTRODUCTION AND OBJECTIVE: Unclassified renal cell carcinoma (uRCC) is a rare non-clear cell RCC variant. Next-generation sequencing studies have reported molecular subgroups to be associated with better (MTOR/PI3K) and worse (HIPPO/TP53/DNA damage repair) outcome. High neutrophil-to-lymphocyte ratio (NLR) is a biomarker of inflammatory response and has been shown to be associated with worse prognosis. We aimed to explore the role of NLR in this setting and further assessed the differences in NLR between genomic subgroups. METHODS: After IRB approval a total of 112 patients with uRCC, who underwent molecular profiling, were identified from our internal database. 85 patients with a preoperative complete blood count obtained at the time of diagnosis and comprehensive follow-up data were included. NLR was computed by dividing the absolute neutrophil count by the absolute lymphocyte count (in K/µl). We performed non-parametric hypothesis testing with p≤0.05 defining statistical significance. Cancer-specific survival (CSS) was calculated from the time of pathological diagnosis to the time of death or last follow-up. Survival estimates were calculated using uni- and multivariable Cox regression models. RESULTS: The study cohort comprised 51 men and 34 women, the median age was 60.5 years (IQR: 51.5-70). The median NLR was 3.05 K/µl (IQR: 2.04-4.2). Patients with higher NLR showed poor CSS (Cox p<0.001, HR 1.23, 95%CI: 1.12-1.36). After accounting for pT and M stage, molecular subgroups and the number of driver mutations at multivariable analysis, higher NLR remained significantly associated with poor CSS (p=0.012, HR 1.18, CI: 1.04-1.34 – Fig. 1A). MTOR/PI3K pathway related subgroups were detected in 17 (20.0%) patients, while in 30 cases mutations in genes of other major pathways (HIPPO/TP53/DNA damage repair/cell cycle) were found. There was a significant difference in NLR between genomic subgroups (Kruskal-Wallis p=0.002, Fig. 1B). CONCLUSIONS: NLR is significantly associated with clinical outcome in uRCC. Further studies are warranted to investigate its value as a biomarker of disease aggressiveness. Moreover, distinct genomic subgroups of uRCC vary considerably with respect to this parameter. Source of Funding: This research was funded in part through the NIH/NCI Cancer Center Support Grant P30 CA008748 © 2021 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 206Issue Supplement 3September 2021Page: e281-e281 Advertisement Copyright & Permissions© 2021 by American Urological Association Education and Research, Inc.MetricsAuthor Information Julian Marcon More articles by this author Renzo G. DiNatale More articles by this author Stanley Weng More articles by this author Mazyar Ghanaat More articles by this author Andrew W. Silagy More articles by this author Roy Mano More articles by this author Kyle A. Blum More articles by this author Kyrollis Attalla More articles by this author Ed Reznik More articles by this author Maria I. Carlo More articles by this author Robert J. Motzer More articles by this author Jonathan A. Coleman More articles by this author Paul Russo More articles by this author A. Ari Hakimi More articles by this author Ying-Bei Chen More articles by this author Expand All Advertisement Loading ...